UNSPSC 51271707: Phenacaine hydrochloride anhydrous

This classification denotes an anesthetic agent with the molecular formula C18H22N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2B61HM98KO, chemically known as ethanimidamide, n,n'-bis(4-ethoxyphenol)-, monohydrochloride, but more generally known as phenacaine hydrochloride anhydrous, which bears US NIH Compound Identifier 12113. European Medicines Agency schedules phenacaine hydrochloride anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09743MIG.

Most nations, for tariff purposes, schedule phenacaine hydrochloride anhydrous under HS 29252900. Phenacaine hydrochloride anhydrous bears US NLM identifiers UMLS ID C2827603 and NCI Concept Code C85245. SMILES: CCOC1CCC(CC1)N/C(=N/C2CCC(CC2)OCC)/C.CL.

UNSPSC 51271707 Phenacaine hydrochloride anhydrous is a Commodity code covering a local anesthetic pharmaceutical ingredient that state and local governments procure primarily through cooperative purchasing agreements for distribution to healthcare facilities and public health programs. Based on recent solicitation activity, this code encompasses the supply of specific pharmaceutical products identified by National Drug Code (NDC), requiring vendors to maintain relationships with authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act requirements. State and local buyers under this code include multistate cooperative purchasing alliances, state health departments, and their member facilities across participating jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body for this commodity, soliciting manufacturers and distributors to establish master agreements that serve multiple member states and localities.

MMCAP's January 2026 RFP for Generic Multi Source Pharmaceuticals and OTC Products (S1070000015802, due March 26, 2026) is the primary recent opportunity under this code, establishing multiple contracts effective July 1, 2026, with a two-year initial term and optional extensions through June 30, 2028. The solicitation spans multiple states including Minnesota and Oregon, with participating state and local government facilities accessing awarded products through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must submit detailed product specifications including NDC codes, SKUs, UPCs, dosage forms, and manufacturing locations, with evaluation weighted heavily toward price competitiveness (75 percent), compliance with administrative format requirements (5 percent), EDI capability (5 percent), fixed pricing (10 percent), and acceptance of a 3 percent administrative fee (5 percent). All products must be available in the marketplace by May 15, 2026, with minimum six-month shelf life and at least one year expiration dates from manufacture.